Exelixis

American biotechnology company

EXEL Nasdaq SEC CIK 939767 LEI 254900PJQB59O2O95R37
Follow Exelixis Weekly email: filings, results

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$1B$0$1B$2B$3BFY12FY14FY16FY18FY20FY22FY24FY26
Show the numbers
YearRevenueNet income
FY26$2.3B$782.6M
FY25$2.2B$521.3M
FY24$1.8B$207.8M
FY23$1.6B$182.3M
FY22$1.4B$231.1M
FY21$987.5M$111.8M
FY20$967.8M$321M
FY19$853.8M$690.1M
FY18$452.5M$154.2M
FY17$191.5M−$70.2M
FY16$37.2M−$161.7M
FY15$25.1M−$261.3M
FY14$31.3M−$238.2M
FY13$47.5M−$145.3M
FY12$289.6M$75.7M
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−1500%−1000%−500%0%500%FY12FY14FY16FY18FY20FY22FY24FY26
Show the numbers
YearGross marginOperating marginNet margin
FY2696.4%37.6%33.7%
FY2596.5%27.9%24%
FY2496%9.3%11.4%
FY2396.4%12.5%11.3%
FY2296.3%20%16.1%
FY2196.3%11.1%11.3%
FY2096.6%38.2%33.2%
FY1996.9%51.4%80.8%
FY1896.7%36.7%34.1%
FY1796.6%−14.7%−36.7%
FY1689.5%−326.6%−435.1%
FY1591.9%−893.9%−1040.6%
FY1496.4%−640.5%−760.1%
FY13100%−258%−306.3%
FY12100%30.9%26.1%
Free cash flowOperating cash flow minus capital expenditure
−$500M$0$500M$1BFY12FY14FY16FY18FY20FY22FY24FY26
Show the numbers
YearFree cash flow
FY26$875.8M
FY25$671.5M
FY24$292.9M
FY23$334.9M
FY22$346.6M
FY21$178.6M
FY20$514.1M
FY19$382.4M
FY18$144.5M
FY17$208.7M
FY16−$141.5M
FY15−$235.9M
FY14−$200.9M
FY13−$125.9M
FY12−$160.2M
Returned to shareholdersDividends paid and shares bought back
$0$250M$500M$750M$1BFY12FY14FY16FY18FY20FY22FY24FY26
Show the numbers
YearBuybacks
FY26$947.5M
FY25$652M
FY24$550.4M
FY23$0
FY22$0
FY21-
FY20-
FY19-
FY18-
FY17-
FY16-
FY15-
FY14-
FY13-
FY12-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Exelixis
  • Healthcare median
−1500%−1000%−500%0%500%FY12FY14FY16FY18FY20FY22FY24FY26
Show the numbers
YearExelixisHealthcare median
FY2633.7%−11.1%
FY2524%−30.6%
FY2411.4%−47%
FY2311.3%−58%
FY2216.1%−80.4%
FY2111.3%−71.9%
FY2033.2%−62.2%
FY1980.8%−46.3%
FY1834.1%−49.6%
FY17−36.7%−45.9%
FY16−435.1%−36%
FY15−1040.6%−38.4%
FY14−760.1%−35.5%
FY13−306.3%−37.1%
FY1226.1%−29.1%